Statements (45)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
alkaloid
anticholinergic drug |
| gptkbp:administeredBy |
injection
oral tablet transdermal patch |
| gptkbp:affiliatedWith |
gptkb:WHO_Model_List_of_Essential_Medicines
|
| gptkbp:alsoKnownAs |
scopolamine
|
| gptkbp:ATCCode |
A03BA03
|
| gptkbp:brand |
Buscopan
Hyoscine butylbromide Hyoscine hydrobromide Kwells Scopoderm Transderm Scop |
| gptkbp:CASNumber |
51-34-3
|
| gptkbp:chemicalFormula |
C17H21NO4
|
| gptkbp:contraindication |
glaucoma
prostatic hypertrophy |
| gptkbp:discoveredBy |
gptkb:Albert_Ladenburg
|
| gptkbp:discoveredIn |
1880
|
| gptkbp:eliminationHalfLife |
8 hours
|
| gptkbp:excretion |
renal
|
| gptkbp:foundIn |
plants of the Solanaceae family
|
| https://www.w3.org/2000/01/rdf-schema#label |
hyoscine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
muscarinic acetylcholine receptor antagonist
|
| gptkbp:meltingPoint |
59–61 °C
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:molecularWeight |
303.35 g/mol
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
intramuscular subcutaneous transdermal intravenous |
| gptkbp:sideEffect |
blurred vision
drowsiness dry mouth urinary retention |
| gptkbp:UNII |
7M19JJG44Q
|
| gptkbp:usedFor |
motion sickness
postoperative nausea and vomiting gastrointestinal spasms |
| gptkbp:bfsParent |
gptkb:Scopolamine
|
| gptkbp:bfsLayer |
7
|